Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia

The transcription factor C/EBPα (for CCAAT/enhancer binding protein-α; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPα triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPα DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.

[1]  C. Calkhoven,et al.  Translation start site multiplicity of the CCAAT/enhancer binding protein alpha mRNA is dictated by a small 5' open reading frame. , 1994, Nucleic acids research.

[2]  L. Wolff.  Contribution of oncogenes and tumor suppressor genes to myeloid leukemia. , 1997, Biochimica et biophysica acta.

[3]  K. Johnson.  An Update. , 1984, Journal of food protection.

[4]  S. McKnight,et al.  The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. , 1988, Science.

[5]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[6]  S. McKnight,et al.  Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. , 1990, Genes & development.

[7]  D. Tenen,et al.  Optimization of transient transfection into human myeloid cell lines using a luciferase reporter gene. , 1991, Experimental hematology.

[8]  D. Tenen,et al.  PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. , 1996, Blood.

[9]  M. Kozak.  The scanning model for translation: an update , 1989, The Journal of cell biology.

[10]  D. Tenen,et al.  CCAAT/Enhancer Binding Protein α Is a Regulatory Switch Sufficient for Induction of Granulocytic Development from Bipotential Myeloid Progenitors , 1998, Molecular and Cellular Biology.

[11]  J. P. Condreay,et al.  Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. , 1996, Cancer research.

[12]  M. Lane,et al.  CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Umek,et al.  CCAAT-enhancer binding protein: a component of a differentiation switch. , 1991, Science.

[14]  S. McKnight,et al.  Isolation of a recombinant copy of the gene encoding C/EBP. , 1988, Genes & development.

[15]  J. R. Smith,et al.  CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. , 1996, Genes & development.

[16]  E. Ziff,et al.  Three levels of functional interaction determine the activity of CCAAT/enhancer binding protein-alpha on the serum albumin promoter. , 1994, Genes & development.

[17]  U. Schibler,et al.  CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Licht,et al.  Transcription factors, normal myeloid development, and leukemia. , 1997, Blood.

[19]  D. Tenen,et al.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P.,et al.  Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT y enhancer binding protein « -deficient mice , 1997 .

[21]  B. Trask,et al.  The CCAAT/enhancer binding protein (C/EBPα) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBPβ) gene (CEBPB) maps to human chromosome 20q13.1 , 1992 .

[22]  R. Umek,et al.  Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. , 1991, Genes & development.

[23]  J. Schalkwijk,et al.  Transcription Factor C/EBPα: Novel Sites of Expression and Cloning of the Human Gene , 1997, Biological chemistry.

[24]  C. Barlow,et al.  Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[26]  U. Schibler,et al.  A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the sam mRNA , 1991, Cell.

[27]  大里 元美.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2 α B gene associated with myeloblastic leukemias , 1999 .

[28]  A. Chumakov,et al.  C/EBP-ε: Chromosomal mapping and mutational analysis of the gene in leukemia and preleukemia , 1997 .

[29]  J. Downing,et al.  The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation , 1998, Molecular and Cellular Biology.

[30]  C. Hsieh,et al.  Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide-mediated acute-phase response , 1996, Molecular and cellular biology.

[31]  G. Darlington,et al.  Inhibition of cell proliferation by C/EBPα occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen , 1995 .

[32]  O. MacDougald,et al.  A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Lekstrom‐Himes,et al.  CCAAT/Enhancer Binding Protein ɛ Is Critical for Effective Neutrophil-Mediated Response to Inflammatory Challenge , 1999 .

[34]  Steven M. Holland,et al.  Neutrophil-specific Granule Deficiency Results from a Novel Mutation with Loss of Function of the Transcription Factor CCAAT/Enhancer Binding Protein ε , 1999, The Journal of experimental medicine.